AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Recruiting

Phase 1

Phase 2

AMT-260AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Sponsor:

UniQure Biopharma B.V.

Code:

NCT06063850

Conditions

Mesial Temporal Lobe Epilepsy

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

AAV9-hSyn1-miGRIK2

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-15. This information was provided to ClinicalTrials.gov by UniQure Biopharma B.V. on 2025-09-04.